Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001973379-25-000282
Filing Date
2025-11-04
Accepted
2025-11-04 16:00:23
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3096
  Complete submission text file 0001973379-25-000282.txt   4648
Mailing Address C/O KERYX BIOPHARMACEUTICALS 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address
Kaye Jack (Reporting) CIK: 0001376099 (see all company filings)

Type: 144

Mailing Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP 1-339-970-7000
uniQure N.V. (Subject) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-36294 | Film No.: 251448771
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)